↓ Skip to main content

Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial

Overview of attention for article published in Experimental Hematology & Oncology, May 2023
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#11 of 389)
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

twitter
37 X users

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
Published in
Experimental Hematology & Oncology, May 2023
DOI 10.1186/s40164-023-00409-y
Pubmed ID
Authors

Xiaohui Suo, Fang Zheng, Dongmei Wang, Liyun Zhao, Jie Liu, Ling Li, Zhihua Zhang, Congcong Zhang, Yinling Li, Sisi Yang, Xuemei Zhao, Rui Shi, Yan Wu, Zongjiu Jiao, Jiaojie Song, Ling Zhang, Xinxiao Lu, Linyu Yuan, Sifeng Gao, Jilei Zhang, Xingli Zhao, Guanchen Bai, Kaiqi Liu, Yingchang Mi

X Demographics

X Demographics

The data shown below were collected from the profiles of 37 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 10%
Student > Doctoral Student 1 10%
Unknown 8 80%
Readers by discipline Count As %
Unspecified 1 10%
Medicine and Dentistry 1 10%
Unknown 8 80%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2023.
All research outputs
#1,534,087
of 25,985,060 outputs
Outputs from Experimental Hematology & Oncology
#11
of 389 outputs
Outputs of similar age
#30,837
of 404,167 outputs
Outputs of similar age from Experimental Hematology & Oncology
#1
of 16 outputs
Altmetric has tracked 25,985,060 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 389 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 404,167 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.